Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Interpace Diag Group (IDXG)

Interpace Diag Group (IDXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 7,913
  • Shares Outstanding, K 4,420
  • Annual Sales, $ 46,930 K
  • Annual Income, $ 6,700 K
  • EBIT $ 6 M
  • EBITDA $ 6 M
  • 60-Month Beta 1.05
  • Price/Sales 0.19
  • Price/Cash Flow 0.72
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.04 on 11/12/25
  • Next Earnings Date 03/30/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Services

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0200 +71.57%
on 12/30/25
1.7900 -2.23%
on 01/21/26
+0.5500 (+45.83%)
since 12/19/25
3-Month
0.8055 +117.26%
on 11/19/25
1.7900 -2.23%
on 01/21/26
+0.8025 (+84.70%)
since 10/21/25
52-Week
0.4433 +294.77%
on 04/25/25
1.7900 -2.23%
on 01/21/26
+0.8000 (+84.21%)
since 01/21/25

Most Recent Stories

More News
Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure

Preliminary 2025 thyroid testing revenue grew 21% over prior year Initial 2026 guidance of 16% growth in thyroid testing revenue All preferred stock converted to common stock Debt-free...

IDXG : 1.7500 (-2.23%)
Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners

PARSIPPANY, NJ, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced that it has fully repaid its outstanding term loan...

IDXG : 1.7500 (-2.23%)
Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results

  ● Q3 Revenue of $8.8 million   ● Q3 Cash Collections of $10.0 million   ● Q3 Thyroid test volume up 12% year-over-year to record levels   ● Q3 Thyroid revenue...

IDXG : 1.7500 (-2.23%)
Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting

Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular...

IDXG : 1.7500 (-2.23%)
Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results

  ● Q2 Revenue of $9.2 million   ● Q2 Cash Collections of $10.8 million   ● Q2 Thyroid test volume up 16% year-over-year to record levels   ● Q2 Thyroid revenue...

IDXG : 1.7500 (-2.23%)
Interpace Biosciences Announces First Quarter 2025 Financial and Business Results

IDXG : 1.7500 (-2.23%)
Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

IDXG : 1.7500 (-2.23%)
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results

IDXG : 1.7500 (-2.23%)
PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan

IDXG : 1.7500 (-2.23%)
Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

IDXG : 1.7500 (-2.23%)

Business Summary

Interpace Biosciences Inc. is enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services include molecular diagnostic tests, bioinformatics, and pathology services....

See More

Key Turning Points

3rd Resistance Point 1.8567
2nd Resistance Point 1.8233
1st Resistance Point 1.7867
Last Price 1.7500
1st Support Level 1.7167
2nd Support Level 1.6833
3rd Support Level 1.6467

See More

52-Week High 1.7900
Last Price 1.7500
Fibonacci 61.8% 1.2756
Fibonacci 50% 1.1166
Fibonacci 38.2% 0.9577
52-Week Low 0.4433

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar